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Unprocessed Interleukin-36α Regulates Psoriasis-Like
Skin Inﬂammation in Cooperation With Interleukin-1
Katelynn A. Milora1, Hangfei Fu1, Ornella Dubaz1 and Liselotte E. Jensen1
Generalized pustular psoriasis is a severe skin disease characterized by epidermal hyperplasia, neutrophil-rich
abscesses within the epidermis, and a mixed inﬂammatory inﬁltrate in the dermis. The disease may be caused by
missense mutations in the IL-36 receptor antagonist, IL-36Ra. Curiously, the related IL-1Ra has therapeutic effects
in some of these latter patients. Here, using an experimental mouse model of psoriasiform skin inﬂammation, we
demonstrate in vivo connections between IL-36 and IL-1 expression. After disease initiation, IL-36α-deﬁcient mice
exhibited dramatically diminished skin pathology, including absence of epidermal neutrophils, reduced
keratinocyte acanthosis, and less dermal edema. In contrast, IL-36β and IL-36γ knockout mice developed disease
indistinguishable from that of wild-type mice. The endogenous IL-36α was not processed through proteolysis.
Although IL-36α expression was strongly induced in an IL-1 signaling-dependent manner during disease,
expression of IL-1α was also dependent upon IL-36α. Hence, after being upregulated by IL-1α, IL-36α acts through
a feedback mechanism to boost IL-1α levels. Analyses of double knockout mice further revealed that IL-36α and
IL-1α cooperate to promote psoriasis-like disease. In conclusion, IL-1α and IL-36α form a self-amplifying
inﬂammatory loop in vivo that in patients with insufﬁcient counter regulatory mechanisms may become hyper-
engaged and/or chronic.
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INTRODUCTION
Psoriasis encompasses a number of non-infectious inﬂamma-
tory conditions of the skin (Raychaudhuri et al., 2014).
Generalized pustular psoriasis (GPP) is the most severe form
involving not only skin inﬂammation, but also systemic
symptoms such as fever and malaise. GPP skin inﬂammation
is characterized by reddening of the skin and formation
of epidermal pustules ﬁlled with neutrophils. When large
areas of the skin are affected by GPP, the condition can be
life-threatening. Palmoplantar pustulosis affects speciﬁcally
the hands and feet, and like GPP involves formation of
neutrophil-containing pustules in the epidermis. The most
common form of psoriasis is plaque psoriasis. This disease is
characterized by red plaques of inﬂamed skin, which are
often scaly owing to dysregulated differentiation of the
epidermis. Although pustules do not form in plaque psoriasis
per se, increased neutrophil recruitment into the epidermis is
still observed. Typically, these neutrophils cluster together
within the stratum corneum of the epidermis and are known
as Munro’s microabscesses.
The etiology of the different types of psoriasis is poorly
understood; however, a seminal advancement of our knowl-
edge was made in 2011, when missense mutations within
the gene, IL36RN, encoding the IL-36 receptor antagonist
(IL-36Ra) were identiﬁed in patients with GPP (Marrakchi
et al., 2011; Onoufriadis et al., 2011). IL-36Ra is a natural
inhibitor of three related cytokines: IL-36α, IL-36β, and IL-36γ
(formerly known as IL-1F6, IL-1F8, and IL-1F9, respectively).
The physiological function of the IL-36 cytokines remains
unknown; however, they were linked to psoriasis pathology
even before the discovery of the IL36RN mutations. Early
studies using transgenic mice overexpressing IL-36α in
keratinocytes revealed skin inﬂammation with some resem-
blance to psoriasis (Blumberg et al., 2007). Furthermore,
several studies have observed increased IL-36α and IL-36γ
mRNA expression in plaque psoriatic skin (reviewed in
Jensen, 2010).
Imiquimod is a ligand for toll-like receptor 7 (Colak et al.,
2014) and adenosine receptors (Schön et al., 2006; Kan et al.,
2012), and has therapeutic effects in humans against basal
cell carcinomas, actinic keratoses, and warts caused by
human papillomaviruses. A known side effect of the drug is
psoriasiform skin inﬂammation (Gilliet et al., 2004; Wu et al.,
2004; Fanti et al., 2006; Rajan and Langtry, 2006; van der Fits
et al., 2009; Patel et al., 2011). This has been exploited to
develop a mouse model of psoriasis, which has rapidly
become very popular owing to its strong resemblance to the
human condition (reviewed in Flutter and Nestle, 2014).
Using the imiquimod-induced psoriasiform skin inﬂammation
model, we previously demonstrated that IL-1R1 signaling, via
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the chemokines CXCL1 and CXCL2, has an essential role in
recruiting neutrophils to the epidermis (Uribe-Herranz et al.,
2013). Furthermore, IL-1, here referring to both IL-1α
and IL-1β, promoted psoriasis-like epidermal hyperplasia via
IL-1α as the dominant form of the two cytokines expressed
in the model (Uribe-Herranz et al., 2013). Given the
recently identiﬁed genetic link between IL-36 and excessive
epidermal recruitment of neutrophils (Marrakchi et al., 2011;
Onoufriadis et al., 2011) in addition to the overexpression
of IL-36 in plaque psoriasis (Jensen, 2010), we here
examined the role of the IL-36 cytokines and their interplay
with the IL-1 axis in the imiquimod-induced psoriasis
mouse model.
RESULTS
IL-36α, but not IL-36β or IL-36γ, is essential for the
development of psoriasiform skin disease
Although the IL-36 cytokines have been linked to inﬂammatory
responses, their physiological functions remain unknown.
Curiously, there are three agonist IL-36 cytokines, but only
one receptor, IL-36R. With the long-term goal of elucidating
the role of this apparent redundancy, we assembled a portfolio
of knockout (KO) mice representing each individual IL-36
cytokine (Supplementary Table S1 online and Supplementary
Figures S1 online). The strains have no apparent defects or
obvious phenotypes. This is in agreement with studies
involving IL-36R− /− mice (Blumberg et al., 2007, 2010;
Tortola et al., 2012; Vigne et al., 2012; Lamacchia et al.,
2013). Because IL-36 signaling has recently been linked to GPP
(Marrakchi et al., 2011; Onoufriadis et al., 2011), we examined
the role of each individual IL-36 cytokine in the imiquimod-
induced psoriasis model (Figure 1 and Supplementary Figure
S3 online). Somewhat surprisingly, we found that while
ablation of neither IL-36β nor IL-36γ affected the imiquimod-
induced phenotype, IL-36α KO mice exhibited a dramatically
reduced phenotype compared with wild-type mice (Figure 1
and Supplementary Figure S3 online). Externally, the IL-36α KO
skin appeared thinner, less red, and less scaly (Figure 1a). In
agreement with these observations, histological and immuno-
histochemical analyses revealed reduced epidermal acanthosis
(Figure 1c and e and Supplementary Figure S3a online) and
dermal edema (Figure 1c and Supplementary Figure S3c
online) in IL-36α KO mice compared with wild type. These
results demonstrate that IL-36α, but not IL-36β or IL-36γ, has a
signiﬁcant role in driving the imiquimod-associated psoriasi-
form skin pathology.
Formation of neutrophil-rich microabscesses in the epidermis is
IL-36α-dependent
A characteristic feature of psoriasis is diffuse neutrophilic
dermal inﬂammation and especially formation of epidermal
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Figure 1. IL-36α has a signiﬁcant role in psoriasiform skin disease induced by imiquimod. Wild-type, IL-36α− /−, IL-36β− /−, and IL-36γ− /− mice were treated
with imiquimod for 4 days. The day after the last application anesthetized (a) or killed (b) mice were photographed and skin collected after being killed. Control
mice were denuded and left untreated until skin collection. Skin was examined by H&E staining (c and d) and immunohistochemistry for PCNA (e and f).
Representative images from ﬁve (IL-36α− /− and IL-36β− /−) and three (IL-36γ− /−) independent imiquimod experiments are shown. Blue scale bars=200 μm. Black
scale bars= 50 μm. H&E, hematoxylin and eosin; PCNA, proliferating cell nuclear antigen.
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abscesses containing neutrophils (Raychaudhuri et al., 2014).
Our previous studies of IL-1 signaling in the imiquimod model
demonstrated that IL-1 has a crucial role in the formation of
such abscesses (Uribe-Herranz et al., 2013). Similar analyses
here revealed that IL-36α KO mice had diminished dermal
inﬁltration by neutrophils and fewer epidermal microabscesses
than wild-type mice (Figure 2 and Supplementary Figure S4
online). No differences between wild-type and either IL-36β-
or IL-36γ-deﬁcient mice could be detected (Figure 2 and
Supplementary Figure S4 online). This, in agreement with the
above-described IL-36α-dependent phenotypes, demonstrates
that of the three IL-36 cytokines, IL-36α is the primary driver of
neutrophil recruitment to the epidermis in the utilized skin
inﬂammation model.
Neutrophil recruitment to IL-36α-deﬁcient epidermis can be
rescued through CXCL1
The neutrophil chemotactic CXCL1 is expressed at elevated
levels in psoriasis (see Uribe-Herranz et al., 2013 for reference)
and human IL-36α stimulates CXCL1 production by human
keratinocytes (Foster et al., 2014). Using mouse keratinocytes,
we observed that mouse IL-36α induced CXCL1 mRNA
(Figure 3a) and protein (data not shown) in a transient and
concentration-dependent manner. Furthermore, in vivo levels of
CXCL1 secreted from inﬂamed skin were lower in IL-36α KO
mice compared with wild type (Figure 3b). In the imiquimod
model, we have shown that neutrophils are recruited to the
epidermis in an IL-1-dependent manner via, for example,
CXCL1 (Uribe-Herranz et al., 2013). In the IL-36α KO mice,
topical application of physiologically relevant levels of CXCL1
(Figure 3b) caused the formation of inﬂammatory foci in the skin
(Figure 3c) and recruitment of neutrophils to the epidermis and
dermis (Figure 3d). The latter demonstrates that the migratory
capacity of the neutrophils is intact in the IL-36α KO mice.
Overall, these observations suggest that IL-36α promotes
neutrophil recruitment, at least in part, through CXCL1.
IL-36α is produced and secreted at high levels in
imiquimod-treated skin
To explore the speciﬁc involvement of IL-36α, but not IL-36β
or IL-36γ, in regulating imiquimod-induced skin inﬂamma-
tion, we examined the expression of these. All three IL-36
mRNAs were signiﬁcantly upregulated in response to topical
imiquimod treatment (Supplementary Figure S5a and c
online), with IL-36α being the most dramatically induced
(≅60-fold). IL-36α protein could be detected readily in culture
medium from explanted skin after only two imiquimod
applications (Figure 4a and Supplementary Figure S5d
online). Similar IL-36β and IL-36γ secretion was not detected
(data not shown). Hence, the speciﬁc involvement of IL-36α,
but not IL-36β nor IL-36γ, in the examined skin inﬂammation
model (Figure 1) likely reﬂects the dramatic induction of
IL-36α gene expression (Supplementary Figure S5a online)
and the subsequent correspondingly high protein levels
achieved (Figure 4a and Supplementary Figure S5d online).
We previously reported that imiquimod induces expression
of IL-1α and IL-1β both in vitro and in vivo (Uribe-Herranz
et al., 2013). In comparison, we here found that the IL-36α, but
not IL-18, mRNA is induced at higher concentrations
(Supplementary Figure S6 online) than those activating
IL-1α and IL-1β gene expression (Uribe-Herranz et al., 2013).
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Figure 2. IL-36α, but not IL-36β or IL-36γ, is required for neutrophil
recruitment. Wild-type (a and b), IL-36α− /− (a), IL-36β− /− (a) and IL-36γ− /−
(b) mice were treated with imiquimod for 4 days as described in Figure 1. Skin
was collected the day after the last imiquimod application and examined by
H&E staining or immunohistochemistry for neutrophils (Ly-6G/Ly-6C). Red
arrows indicate Munro’s microabscesses (clusters of neutrophils) at the top of
the epidermis. Black arrows indicate individual neutrophils within the dermis.
Representative images from the experiments also analyzed in Figure 1
and Supplementary Figure S3 online are shown. Scale bars= 50 μm. H&E,
hematoxylin and eosin.
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Despite the dramatic induction of the IL-36α mRNA
(Supplementary Figure S6 online), we were not able to detect
IL-36α protein production (data not shown). This is in
agreement with our reported observations that these drug
levels are cytotoxic to cultured keratinocytes (Uribe-Herranz
et al., 2013). Given the topical application of imiquimod in
the here-used mouse model, it is difﬁcult to assess the drug
concentrations experienced by the epidermal keratinocytes;
however, it is possible that imiquimod has a signiﬁcant role as
a direct activator of IL-36α gene expression in this model.
IL-36α is released in an inﬂammatory caspases-independent
manner
A curious characteristic of IL-1 and IL-36 cytokines is that
they lack signal peptides for conventional protein secretion
(reviewed in Jensen, 2010). The release mechanism for IL-1β,
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Figure 3. IL-36α may promote neutrophil recruitment through CXCL1. (a) Mouse primary keratinocytes were treated with medium only, IL-1α (10 ng ml−1)
or IL-36α (as indicated). CXCL1 mRNA levels were determined using real-time PCR (means+SD). (b) Wild-type (black circles, n=5) and IL-36α− /− (white circles,
n= 4) mice were treated with imiquimod four times and 4-mm skin biopsies explanted the day after the last drug application. Production of CXCL1 was
examined by ELISA. (c and d) IL-36α− /− mice were treated with imiquimod+PBS or imiquimod+25 ng CXCL1 per mouse twice. External skin appearance was
photodocumented (c) and neutrophil recruitment examined using immunohistochemistry for Ly-6G/Ly-6C (d). Blue arrows, examples of focal inﬂammation
(red spots). Black arrows, examples of neutrophils (Ly-6G/Ly-6C-positive cells). Red arrows, regions enlarged in × 40 images. Black bars= 200 μm. Blue
bars=50 μm. *Po0.05; **Po0.01; ***Po0.001. PBS, phosphate-buffered saline.
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Figure 4. Topical imiquimod treatment leads to dramatic induction and secretion of unprocessed IL-36α in an inﬂammatory caspases-independent manner.
(a) Wild-type mice (n=3–5 per time point) were treated with imiquimod as indicated. Skin was collected and used for 4-mm explant cultures. Levels of secreted
IL-36α were examined by western blotting. (b) Wild-type and Casp1− /−/Casp4− /− mice (n=4 per group) were treated with imiquimod four times and IL-36α
secretion examined. (c) Two independent samples of secreted proteins (wild type 1 and wild type 2) were analyzed by western blotting next to full-length
recombinant IL-36α (IL-36α (1–160)) and predicted processed short recombinant IL-36α (IL-36α (8–160)) in EpiLife medium.
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which is the best characterized, often involves the inﬂam-
masomes and the inﬂammatory caspases caspase-1 and
caspase-4 (Shin and Brodsky, 2015). In macrophages,
imiquimod induces IL-1β secretion through NLRP3
inﬂammasome-mediated activation of caspase-1 (Kanneganti
et al., 2006). We previously established that the release of
IL-36γ from cells treated with double-stranded RNA is
dependent upon the inﬂammatory caspases (Lian et al.,
2012), whereas IL-1α release during herpes simplex virus-1
infection is caspase-1/-4–independent (Milora et al., 2014).
Hence, we examined whether IL-36α release in the here-
utilized imiquimod model was dependent or independent of
the inﬂammatory caspases. Interestingly, our data revealed
that IL-36α release is independent of caspase-1 and -4
(Figure 4b). This suggests an IL-36α release mechanism
distinct from that controlling IL-1β.
IL-36α does not undergo processing in vivo
On the basis of size, the IL-36 cytokines were predicted
upon discovery to be synthesized as mature proteins unlike
the related IL-1β, which requires proteolytic cleavage for
activation and extracellular release (Shin and Brodsky,
2015). Full-length recombinant IL-36 proteins, expressed
in bacteria, are active, albeit only at high concentrations
(see Jensen, 2010 for reference). Through genetic engineering, it
has been demonstrated that truncation of 17 amino acids
from the N-terminus of IL-36γ led to enhanced activity (Towne
et al., 2011). Curiously, removal of fewer, or more, amino
acids did not have similar effects. Consequently, it was
proposed that the IL-36 cytokines require proteolytic proces-
sing, at very speciﬁc sites, to be activated (Towne et al., 2011).
By sequence comparison, processing of mouse IL-36α was
predicted to involve seven amino acids ((Towne et al., 2011),
shown in blue in Supplementary Figure S1b online). To
determine whether IL-36α is processed in vivo, we examined
the molecular weight of secreted endogenous IL-36α compared
with full-length and truncated (predicted) recombinant proteins.
Interestingly, we found that endogenously secreted IL-36α
migrated identically to full-length recombinant IL-36α
(Figure 4c). Consequently, we conclude that IL-36α is released
as an unprocessed protein.
IL-36α expression is induced by IL-1 in vitro and in vivo
In vitro studies have established that IL-1β can stimulate
expression of the human IL-36α mRNA in bronchial epithelial
cells (Chustz et al., 2011). In a similar manner, we found
that mouse IL-1α induced IL-36α gene expression in mouse
keratinocytes (Figure 5a). We previously demonstrated
that IL-1 signaling, via IL-1R1 and primarily IL-1α, has an
essential role in initiating skin disease in the imiquimod
model (Uribe-Herranz et al., 2013). Hence, we hypo-
thesized that IL-1α signaling could be involved in driving
the inducible expression of IL-36α found in vivo (Figure 4
and Supplementary Figure S5 online). Consistent with this
hypothesis, we observed signiﬁcantly lower levels of IL-36α
secretion from inﬂamed IL-1R1-deﬁcient skin than wild type
(Figure 5b). Hence, IL-1α is an important regulator of IL-36α
expression in vivo.
IL-36α regulates IL-1α in a feedback loop
Ex vivo studies of peripheral blood mononucleated cells from a
single patient with GPP and a healthy control revealed
potentiated activation of IL-1α gene expression in GPP cells
in response to IL-36α (Onoufriadis et al., 2011). Using primary
mouse keratinocytes, we observed rapid induction of the IL-1α
mRNA in response to IL-36α (Figure 5c). In the mouse model of
psoriasis we used, we observed progressive upregulation of
IL-1α mRNA during disease development (Supplementary
Figure S7 online). This is in agreement with our previously
reported data demonstrating upregulation of IL-1α protein
(Uribe-Herranz et al., 2013). The induction of IL-1α correlated
with increased IL-36α mRNA and protein expression (Figure 4
and Supplementary Figure S5 online), and we therefore
examined whether the inducible IL-1α expression was depen-
dent, at least in part, upon IL-36α. Indeed, we found that levels
of IL-1α released from imiquimod-treated skin were signiﬁ-
cantly lower in the absence of IL-36α than in the presence of
IL-36α (Figure 5d). Levels of IL-18 (Supplementary Figure S8
online), but not IL-1β and IL-17A (not shown), were also found
to be IL-36α-dependent. Hence, we conclude that once
expression of IL-36α is initiated, via IL-1R1 signaling (Figure
5a and b), IL-36α feeds back to induce IL-1α expression (Figure
5c and d).
IL-1α and IL-36α cooperate to promote epidermal hyperplasia,
dermal edema, and chemokine production
Previously, we showed that IL-1R1 signaling has a signiﬁcant
role in initiating epidermal hyperplasia and neutrophil recruit-
ment through CXCL1 in response to imiquimod (Uribe-Herranz
et al., 2013). As IL-36α expression is induced via IL-1R1 (Figure
5a and b), we wondered whether IL-36α acts downstream of
IL-1 in a sequential linear pathway or whether the two
cytokines act together when present at the same time. To
address this, we generated IL-36α and IL-1R1 double KO
mice and compared epidermal hyperplasia, dermal edema,
and CXCL1 expression with that induced in single KO mice
(Figure 5e and g). In IL-36α− /−/IL-1R1− /−mice, the thickness of
both the epidermis (Figure 5e) and the dermis (Figure 5f) was
signiﬁcantly thinner than that in single KO mice. Additionally,
production of the neutrophil chemotactic CXCL1 was reduced
in the IL-36α− /−/IL-1R1− /− mice compared to single KO mice
(Figure 5g). This demonstrates that once the expression of
IL-36α is induced, IL-1α and IL-36α act together in vivo to
promote psoriasiform skin disease.
DISCUSSION
The discovery of missense mutations in IL36RN causing
generalized GPP (Marrakchi et al., 2011; Onoufriadis et al.,
2011) implicates the overzealous IL-36 signaling in the
disease pathology. Here, we show that in the imiquimod-
induced psoriasiform skin disease model, IL-36α is the
primary form of IL-36 driving skin pathology, including
epidermal hyperplasia, dermal inﬂammation, and neutrophil
recruitment to the epidermis (Figures 1 and 2 and Supple-
mentary Figure S4 online). The active form of IL-36α is,
against expectations, not proteolytically processed in con-
nection with its release from cells (Figure 4c). Our study
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further reveals that elevated expression of both IL-36α and
IL-1α are intricately linked during disease, as each cytokine is
involved in regulating expression of the other (Figure 5a
and d). Through this mutual induction, IL-36α and IL-1α
act together to boost the pathogenic function of the other
cytokine’s signaling pathway (Figure 5e and g).
Anakinra, recombinant human IL-1Ra, has been success-
fully used off label to treat individual cases of GPP asso-
ciated with IL-36Ra missense mutations (Rossi-Semerano
et al., 2013; Hüffmeier et al., 2014). Analyses of cytokine
production by peripheral blood mononuclear cells from a
patient with GPP revealed elevated IL-1α production in
response to IL-36α compared with a healthy control sample
(Onoufriadis et al., 2011). In the in vivo model we used, IL-1α
is indeed a downstream target of IL-36α signaling (Figure 5d).
Interestingly, we also ﬁnd that IL-36α expression is dependent
upon IL-1 signaling (Figure 5b), suggesting feedback mechan-
isms between the IL-1 family cytokines (Supplementary
Figure S9 online). Owing to this inter-regulation, IL-1α and
IL-36α form a self-amplifying cycle (Supplementary Figure S9
online), which may run out of control in the absence of proper
regulatory mechanisms such as the IL-1Ra and IL-36Ra. This
cycle may not only explain the often sudden and dramatic
disease ﬂares seen in patients with inﬂammatory diseases, for
example GPP, but may also pinpoint the chronic nature
of these conditions. As such, this cycle (Supplementary
Figure S9 online) may represent an ideal therapeutic target
to restore homeostatic balance.
In addition to a direct feedback loop between IL-1α and
IL-36α (Figure 5a and d and Supplementary Figure S8 online),
additional factors may contribute to further ampliﬁcation of
the pathogenic process. The IL-1 and IL-36 cytokines regulate
their own expression (Carrier et al., 2011; Uribe-Herranz
et al., 2013 and references therein); hence, they further fuel
the process (Supplementary Figure S9 online). A second
connected cycle of ampliﬁcation may involve other cytokines
(Supplementary Figure S9 online) as IL-36 expression is
directly induced in keratinocytes by IL-17A, IL-22, and TNF-α
(Carrier et al., 2011), and expansion of IL-17 producing γδ
T cells is IL-36-dependent (Tortola et al., 2012). Interestingly,
IL-36R KO mice exhibit a milder imiquimod-induced pheno-
type than mice deﬁcient of factors from the well-known IL-23/
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Figure 5. IL-36α and IL-1 cooperate to drive psoriasiform skin inﬂammation through mutual regulation. (a and c) Mouse primary keratinocytes were treated
with medium only, IL-1α (10 ng ml−1) or IL-36α (1 μgml−1) for 1 hour. IL-36α (a) and IL-1α (c) mRNA levels were evaluated using real-time PCR. (b) Wild-type
(n= 4) and IL-1R1 KO (n=3) mice were treated with imiquimod two times. Skin was explanted and maintained for another 24 hours. Levels of IL-36α
secreted into the medium were determined by ELISA. (d) Wild-type (n= 4) and IL-36α− /− (n=4) mice were treated with imiquimod four times. Treated skin
was explanted and levels of IL-1α secreted into the medium determined by ELISA. (e–g) IL-36α (n= 6), IL-1R1 (n=7) and IL-36α/IL-1R1 double KO (n=7)
mice were treated with imiquimod four times. Epidermal (e) and dermal (f) thickness was examined using H&E staining and ImageJ. (g) Levels of CXCL1 secretion
were determined by ELISA. Data points are shown as mean+SD. *Po0.05; **Po0.01; ***Po0.001. H&E, hematoxylin and eosin; KO, knockout.
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IL-17/IL-22 pathogenic axis, suggesting that the IL-36 system
has an additional distinct activity (Tortola et al., 2012).
The here-identiﬁed IL-1α/IL-36α loop may be this activity
(Supplementary Figure S9 online). While Torlola et al. did not
observe an effect of IL-1R1 ablation upon epidermal
acanthosis, our previous (Uribe-Herranz et al., 2013) and
the here-present study did ﬁnd such an effect. This apparent
discrepancy may be due to the different application sites.
Tortola et al. applied imiquimod to the ears, whereas we
apply it to the back as in the original model report (van der
Fits et al., 2009). The acanthosis observed in the ears is
signiﬁcantly milder (Tortola et al., 2012) than that observed in
the back skin (van der Fits et al., 2009) (Figures 1 and 2
and Supplementary Figure S3 online). Hence, the IL-1R1-
dependent phenotype may be missed in the ear-version of
the model. Consequently, caution should be taken when
comparing studies utilizing the imiquimod mouse model of
skin inﬂammation.
Keratinocytes appear to be the source of IL-36 in at least
GPP (Marrakchi et al., 2011). Although we readily detected
IL-1-dependent IL-36α expression in the imiquimod model
(Figure 5b), we have not been able to detect protein
production in keratinocyte cultures. This could suggest that
signals, additional to IL-1, are required to achieve the in vivo
observed levels. Such additional factors are also suggested by
our in vivo data demonstrating only a partial reduction in
IL-36α expression in IL-1R1 KO mice (Figure 5b) compared
with the dramatic full induction (Figure 4a and Supplementary
Figure S5 online). IL-17 A may be one such factor as it
activates IL-36 mRNA expression in vitro (Carrier et al., 2011).
Although we did not observe a difference in IL-17A levels at
the here-examined time-point associated with the skin
phenotype, IL-17A is known to be transiently induced in the
model (van der Fits et al., 2009); hence, IL-17A could
contribute to the IL-36α induction at an earlier time point.
Imiquimod cream may also directly induce IL-36α in a
manner distinct, or similar to, that previously described for
IL-1α (Uribe-Herranz et al., 2013; Walter et al., 2013). The
latter is a deviation from human psoriasis pathology where the
disease triggers are poorly understood. Identiﬁcation of
initiator factors in both the imiquimod model and human
pathology may represent new therapeutic and preventive
targets.
In response to inﬂammatory signals, IL-1β is synthesized as
a pro-protein. This pro-IL-1β is cleaved by caspase-1, an
independent signaling event, to gain functional activity
(reviewed in Jensen, 2010). On the basis of genetic
engineering, it has been suggested that the IL-36 cytokines
require similar proteolytic cleavage to be activated (Towne
et al., 2011). Our studies here demonstrate that IL-36α is
released from skin cells in an unprocessed form (Figure 4c).
This unprocessed IL-36α appears to be active, as dramatically
reduced skin pathology is observed in IL-36α-deﬁcient mice
(Figures 1 and 2 and Supplementary Figure S4 online).
Although it was previously shown that IL-36α gained activity
upon removal of seven or ﬁve amino acids from the
N-terminus (mouse (Supplementary Figure S1B online, blue
highlight) vs. human), the full-length IL-36α, unlike IL-1β, still
has signaling capacity (reviewed in Jensen, 2010). The
observed in vivo activity of unprocessed IL-36α reported
here may be due to high local production of the cytokine
leading to a microenvironment conducive for the relatively
low activity of full-length IL-36α. However, it is a possibility
that under conditions different from the here-studied skin
inﬂammation, IL-36α can undergo processing to enhance its
activity, and that the protease involved is not activated in the
here-utilized model.
Interestingly, in vitro processing of IL-36γ appears to be
associated with keratinocyte differentiation, as it is induced by
high calcium concentrations (Li et al., 2014). As epidermal
differentiation is dysregulated in psoriasis and associated with
aberrant calcium levels (Menon and Elias, 1991), it is possible
that the IL-36 processing protease is not activated in psoriatic
skin. If IL-36γ activity is strictly dependent upon processing,
then lack of cleavage could explain the absence of a
phenotypic effect in our IL-36γ− /− mice (Figure 1). IL-36γ is
well known to be upregulated in psoriatic skin (reviewed in
Jensen, 2010), and it has been proposed as a biomarker to
distinguish psoriasis from other inﬂammatory skin conditions
(D'Erme et al., 2015). If IL-36γ is to be considered a
therapeutic target and not just a biomarker, it will be critical
to determine whether IL-36γ is, aside from upregulated,
responsible for disease pathology and/or progression. Such
activity may be dependent upon site-speciﬁc processing and
consequently, it would be very interesting to determine
whether IL-36γ is processed in healthy and diseased
human skin.
In summary, we have linked IL-1α and IL-36α in an in vivo
feedback loop (Supplementary Figure S9 online). Such a loop
could explain both sudden and dramatic disease onset as seen
in, for example GPP, and the chronic nature of psoriatic
diseases. As such, this self-amplifying cycle (Supplementary
Figure S9 online) represents a promising therapeutic target;
however, as discussed above, many questions remain
unresolved. Through further studies, an improved insight into
the mechanisms whereby IL-36 and keratinocytes initiate and
maintain psoriatic disease may reveal novel therapeutic
strategies and targets.
MATERIALS AND METHODS
Mice
IL-1R1 and Casp1/Casp4 deﬁcient mice were obtained from the
Jackson Laboratory. Il1f6+/− mice were generously donated by
GlaxoSmithKline and backcrossed onto the C57BL/6 background.
Il1f9+/− and Il1f8+/− mice were procured from the Mutant Mouse
Regional Resource Center (University of North Carolina) and
Knockout Mouse Project University of California Davis (project ID:
VG13041), respectively. Mice were interbred to generate KO (single
or double) and wild-type mice (all on the C57BL/6 background).
Homozygous founders were used for further breeding. All experi-
mental mice were bred in house in a speciﬁc pathogen-free animal
facility. All housing, breeding, and experimental procedures invol-
ving mice were approved by the Temple University Institutional
Animal Care and Use Committee and in compliance with the U.S.
Department of Health and Human Services Guide for the Care and
Use of Laboratory Animals. Experimental mice (male and female)
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were used at age 8–10 weeks and matched for sex in each
independent experiment.
Genotyping
Mice were genotyped using a previously described protocol (Jensen
et al., 2006). PCR was performed using primers listed in Supple-
mentary Table S2 online.
Flow analyses
Blood was collected by cardiac puncture and erythrocytes lysed with
RBC lysis buffer (eBioscience, San Diego, CA). Neutrophils, monocytes,
and lymphocytes were identiﬁed based on forward and side scatter
using a FACSCanto Cell Analyzer (BD Biosciences, San Jose, CA).
Induction of psoriasiform skin inﬂammation
Mice were denuded by shaving and subsequent treatment
with depilating cream. Imiquimod cream (5%, 62.5mg, Medicis,
Scottsdale, AZ) was applied daily to a 6 cm2 area as indicated for each
experiment. Skin was collected the day after the last application unless
indicated otherwise.
Quantiﬁcation of epidermal and dermal thickness
Phosphate-buffered saline-buffered formaldehyde (4%)-ﬁxed skin
was examined by standard hematoxylin and eosin staining. For each
skin specimen, three independent images were acquired. Epidermal
and dermal thickness was measured in three independent locations
using ImageJ. An average thickness of the epidermis and dermis was
calculated for each tissue. In most experiments, including those
involving double KOs, the measurements were performed blinded to
the strain genotype.
Immunohistochemistry
Neutrophils were detected using rat anti-mouse Ly-6G/Ly-6C anti-
body (BD Biosciences) as previously described (Uribe-Herranz et al.,
2013). Proliferating cell nuclear antigen was visualized using the
PCNA staining kit (Life Technologies, Frederick, MD) according to
the manufacturer’s instructions.
Real-time RT-PCR
RNA was isolated using the RNeasy Plus Universal system (Qiagen,
Valencia, CA) according to the manufacturer’s instructions. RNA was
reverse-transcribed and cDNA analyzed as previously described
(Sanmiguel et al., 2009). Additional primers are listed in Supple-
mentary Table S2 online. Actin was used as the housekeeping gene
for ΔΔCt analyses.
Protein preparations
For analyses of secreted protein levels, standardized 4- mm circular
skin biopsies (Miltex, York, PA) were placed in 200 μl EpiLife
medium supplemented with EDGF (Life Technologies) for 24 hours.
Explant medium was collected for ELISA analyses. Total protein was
extracted from skin in previously described lysis buffer (Jensen and
Whitehead, 2003) using a Bio-Gen PRO200 homogenizer equipped
with interchangeable Multi-Gen 7XL probes (PRO Scientiﬁc, Oxford,
CT). Protein levels were determined using Bio-Rad Protein Assay Dye
Reagent (Bio-Rad, Hercules, CA).
Cell cultures
Human and mouse primary keratinocytes were obtained and
maintained as previously described (Uribe-Herranz et al., 2013).
Mouse cells were treated with mouse cytokines (IL-1α (Peprotech,
Rocky Hill, NJ) and IL-36α (aa 8–160) (R&D Systems, Minneapolis,
MN)) as indicated. Water-soluble imiquimod was from InvivoGen.
ELISA
Sandwich ELISAs (Peprotech (CXCL1, IL-1α) and R&D Systems
(IL-17A and IL-18)) were performed according to the manufacturer’s
instructions. Direct ELISAs for mouse IL-36 were performed as
previously described (Lian et al., 2012). Individual IL-36 cytokines
were detected by sequential incubation with: (i) goat anti-IL-36α
(AF2297, R&D Systems), or goat anti-IL-36β (AF2298, R&D Systems)
and (ii) appropriate species-speciﬁc horseradish peroxidase-
conjugated secondary antibodies. The detection limit for the mouse
IL-36β ELISA was ≈400 pg ml−1 (IL-36α levels were detected in the
500–10,000 pg ml− 1 range).
Western blotting
Proteins were separated by PAGE, transferred to polyvinylidene
diﬂuoride membranes and detected by enhanced chemilumines-
cence using anti-IL-36α (AF2297), anti-IL-36γ (custom synthesized at
Genscript, Piscataway, NJ) or anti-GAPDH (FL-335, Santa Cruz,
Dallas, TX) and appropriate secondary antibodies.
Statistical analyses
All experiments were performed at least three times unless indicated
otherwise. Data shown are arithmetic means± standard deviations
(SD) unless indicated otherwise. Statistical signiﬁcance was
calculated using analysis of variance or students t test.
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